During the past decade, Etelä-Karjalan keskussairaala conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Etelä-Karjalan keskussairaala" are "Amyotrophic Lateral Sclerosis" (1 trials), "Hyperlipidemia" (1 trials) and "Idiopathic Parkinson's Disease" (1 trials). Many other conditions were trialed in "Etelä-Karjalan keskussairaala" in a lesser frequency.

Most popular intervention types in "Etelä-Karjalan keskussairaala" are "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bococizumab (PF-04950615; RN316)" (1 trials), "Levosimendan" (1 trials), "Placebo" (1 trials), "Placebo for levosimendan" (1 trials) and "Safinamide (as add-on therapy)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Etelä-Karjalan keskussairaala" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Etelä-Karjalan keskussairaala". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Etelä-Karjalan keskussairaala, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Etelä-Karjalan keskussairaala, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".